New rare disease platform launched for Hunter Syndrome
Hunter syndrome (MPS II) is a rare condition resulting from mutations in the gene that codes for the production of the lysosomal enzyme iduronate-2-sulfatase (I2S). Recognition and diagnosis at an early stage is crucial to establishing appropriate management strategies.
Please note the Hunter Syndrome Knowledge Centre is not intended for HCPs in USA or UK. It has been developed by EPG Health for Medthority.com, in collaboration with Shire.
Related news and insights
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.